Microbiology & Immunology Infectious Disease Screening and monitoring Research and Innovations

Lyme Antibodies May Improve Test Timing

Study identifies immune markers that could support earlier diagnosis and help distinguish patients with persistent symptoms

07/10/2026 News 2 min read

Share

Clinical Scorecard: Lyme Antibodies May Improve Test Timing

At a Glance

Category	Detail
Condition	Lyme Disease
Key Mechanisms	Antibodies targeting phosphatidic acid and phosphatidylserine may improve early detection of Lyme disease.
Target Population	Patients with Lyme disease, including those with persistent symptoms post-treatment.
Care Setting	Clinical laboratories conducting Lyme disease diagnostics.

Key Highlights

New immune antibodies appear earlier than current laboratory markers of Lyme disease.
Antiphospholipid antibodies may complement existing tests for better early detection.
Persistent elevation of antibodies against phosphatidylserine observed in patients with long-term PTLD.

Guideline-Based Recommendations

Diagnosis

Incorporate antiphospholipid antibodies into multi-marker testing strategies.

Management

Serial measurement of antibodies may support monitoring disease activity.

Monitoring & Follow-up

Antibody levels should be monitored post-treatment, especially in patients with PTLD.

Risks

Current tests may miss early infections and cannot distinguish between active and past infections.

Patient & Prescribing Data

Patients diagnosed with Lyme disease and those experiencing persistent symptoms.

Most patients' antiphospholipid antibody levels decline after treatment, but some with PTLD show persistently raised levels.

Clinical Best Practices

Utilize multi-marker testing strategies to enhance diagnostic accuracy.
Consider the role of antiphospholipid antibodies in identifying biologically distinct subgroups.

Related Resources & Content

Infection and Immunity Study